Masks are still required at all locations. Please read important information about visiting hours and COVID-19 vaccination requirements or testing for some visitors. Read More

Sloan Kettering Institute
Research
- - Changing how the world understands and treats cancer
    Our scientists pursue every aspect of cancer research—from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more.
- - Programs & Centers
  - Sloan Kettering Institute
    Pursuing basic and translational research across 9 programs and 100+ labs
  - Memorial Hospital research
    Focusing on clinical cancer research and population health
  - Human Oncology & Pathogenesis Program (HOPP)
    Bridging the lab and the clinic through translational research
  - Collaborative research centers
    Fostering interdisciplinary collaborations between laboratory scientists and clinicians
  - Extramural collaborations
    Partnering with other academic and research institutions
- - Research at MSK
  - Our research impact
  - Research topics
  - Core facilities & resources
    Offering state-of-the-art resources for our researchers
  - Find a researcher or lab
  - Education & training programs
Education & Training
- - Training the next generation of clinicians and scientists
    Our highly-specialized educational programs shape leaders to be at the forefront of cancer care and research.
- - For Research
  - Postdoctoral training
  - Gerstner Sloan Kettering Graduate School of Biomedical Sciences
    Offering a curriculum with a focus on cancer
  - PhD & MD/PhD programs
  - MSK Bridge program
    Connecting college seniors to future careers in biomedicine
  - High school & undergraduate summer programs
Careers
MSK Direct
- - In the U.S.
  - English
  - Español
  - Pу́сский
  - Outside of the U.S.
  - العَرَبِيَّة
  - Deutsch
  - English
  - Español
  - 한국어
  - עִבְרִית
  - Italiano
  - Português
  - Pу́сский
  - Türkçe
  - 中文

Make an Appointment
- - We’re here for you.
    Make an appointment
    New patient
    Current patient
    Speak to a care advisor
    Adults: 833-920-3234
    Monday to Friday, 8 a.m. to 6 p.m. (Eastern time)
    Children & Teens: 833-MSK-KIDS
    Monday to Friday, 9 a.m. to 5 p.m. (Eastern time)
- - Becoming A Patient
  - How to get started
  - Insurance & financial assistance
  - Preparing for your first appointment
  - Meet our doctors
  - Explore our locations
Refer a Patient
- - Partner with us to treat your patient’s cancer.
    Refer a patient
    Call Physician Access Team
    833-340-1151
    Monday to Friday, 9 a.m. to 5 p.m. (Eastern time)
- - Clinical Resources
  - Our doctors
  - Physician relations
  - Clinical updates & insights
  - Prediction tools
  - Clinical trials
  - Continuing medical education (CME)
Learn About Cancer & Treatment
- - We treat every type of cancer, including the most important one: yours.
    With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need, when you need it.
- - Adults
  - Cancers & conditions
  - Risk assessment & screening
  - Diagnosis & treatment
  - Clinical trials
  - Children & Teens
  - Cancers & conditions
  - Diagnosis & treatment
  - Clinical trials
- - Support, Services & Programs
  - For adults
  - For children & teens
  - For caregivers
  - Adolescents & young adult (AYA) program
  - Patient & caregiver education library
  - Cancer News & Discoveries
  - Read the latest
  - Sign up for our newsletter
About Us
- - We’re always leading the fight against cancer.
    Memorial Sloan Kettering was founded in 1884, and today is a world leader in patient care, research, and educational programs.
- - About Us
  - Leadership
  - History
  - Equality, diversity & inclusion
  - Annual report
  - Give to MSK
  - For the Media
  - Media inquiries
  - News releases
  - News & information
- - Have Questions?
  - Contact us
  - Plan Your Visit
  - Explore our locations
  - Directions
  - Visitor policy
Patient Portal: MyMSK
Donate Now
- Sloan Kettering Institute
- Research
  - - Programs & Centers
    - Sloan Kettering Institute
      Pursuing basic and translational research across 9 programs and 100+ labs
    - Memorial Hospital research
      Focusing on clinical cancer research and population health
    - Human Oncology & Pathogenesis Program (HOPP)
      Bridging the lab and the clinic through translational research
    - Collaborative research centers
      Fostering interdisciplinary collaborations between laboratory scientists and clinicians
    - Extramural collaborations
      Partnering with other academic and research institutions
  - - Research at MSK
    - Our research impact
    - Research topics
    - Core facilities & resources
      Offering state-of-the-art resources for our researchers
    - Find a researcher or lab
    - Education & training programs
- Education & Training
  - - For Research
    - Postdoctoral training
    - Gerstner Sloan Kettering Graduate School of Biomedical Sciences
      Offering a curriculum with a focus on cancer
    - PhD & MD/PhD programs
    - MSK Bridge program
      Connecting college seniors to future careers in biomedicine
    - High school & undergraduate summer programs
- Careers
- MSK Direct
- - - In the U.S.
    - English
    - Español
    - Pу́сский
    - Outside of the U.S.
    - العَرَبِيَّة
    - Deutsch
    - English
    - Español
    - 한국어
    - עִבְרִית
    - Italiano
    - Português
    - Pу́сский
    - Türkçe
    - 中文

Dimiter V. Tassev, PhD

Portfolio Manager ExodusPoint Capital Management, New York, NY

Share

Share

Dimiter V. Tassev

Dissertation

Generation and Use of HLA-A2-Restricted, Peptide-Specific Monoclonal Antibodies and Chimeric Antigen Receptors

Mentor

Nai-Kong V. Cheung, MD, PhD

End Year

2011

Education

The Ohio State University

Publications

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O’Reilly RJ, Cheung NK. (2015) Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia.

Cheung N, Guo H, Hu J, Tassev D, Cheung I. (2012) Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology, 1, 477-486.

Tassev D, Cheng M, Cheung N. (2011) Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther, 19, 84-100.

Tassev D, Cheung N. (2009) Monoclonal Antibody Therapies for Solid Tumors. Expert Opin Biol Ther, 9, 341-353.